<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03047057</url>
  </required_header>
  <id_info>
    <org_study_id>SM12017</org_study_id>
    <nct_id>NCT03047057</nct_id>
  </id_info>
  <brief_title>Lidocaine Infusion in Radical Cystectomy</brief_title>
  <official_title>Effect of Lidocaine Infusion on Acute Rehabilitation After Radical Cystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radical cystectomy (RC) remains the gold standard for treatment of patients with muscle
      invasive bladder cancer, or recurrent high grade non-muscle invasive bladder cancer.
      Nowadays, enhanced recovery pathway is used to decrease morbidity and improve acute
      rehabilitation after RC. Postoperative ileus is the most frequent reason for prolonged
      hospital stay following cystectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radical cystectomy remains the gold standard for treatment of patients with muscle invasive
      bladder cancer, or recurrent high grade non-muscle invasive bladder cancer. The high rates of
      morbidity and mortality reflect the fact that the majority of patients undergoing this
      procedure are elderly patients with multiple comorbidities. Postoperative ileus is the most
      frequent reason for prolonged hospital stay following cystectomy. To reduce the risk of
      ileus, prokinetics such as metoclopramide should be used postoperatively. Local anesthetics
      exert their actions as local anesthesia and antiarrhythmic through Na channels blocking but
      still have many other important actions through other receptors (e.g., m1 muscarinic
      receptors) that occur at very low plasma levels compared to levels needed for Na channels
      blocking, one of these actions is the antiâ€‘inflammatory effect against surgical stress
      response. Several randomized studies found that i.v. lidocaine shortens duration of
      postoperative ileus and some of it reported decreased postoperative pain with i.v. lidocaine,
      so they recommended i.v. lidocaine as a safe, simple, and less invasive method for management
      of postoperative ileus and equal to postoperative epidural analgesia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 3, 2017</start_date>
  <completion_date type="Actual">March 20, 2018</completion_date>
  <primary_completion_date type="Actual">March 20, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative return of gastrointestinal (GI) function</measure>
    <time_frame>15 day</time_frame>
    <description>Time to the first defecation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Pain</measure>
    <time_frame>24 hours after surgery</time_frame>
    <description>a 10 cm visual analog pain scale (VAS) at rest and during mobilization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Postoperative Ileus</condition>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Lidocaine infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV normal saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>IV Lidocaine infusion</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV normal saline</intervention_name>
    <description>IV normal saline infusion</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  45-75 yr ASA class I,II, and III Elective radical cystectomy

        Exclusion Criteria:

          -  Allergy to the study medication, pre-existing chronic pain at any site requiring
             treatment, Psychiatric disease, hepatic or renal impairment, seizure disorder
             requiring medication within the previous 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seham Mohamed Moeen Ibrahim</name>
      <address>
        <city>Asyut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2017</study_first_submitted>
  <study_first_submitted_qc>February 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2017</study_first_posted>
  <last_update_submitted>May 5, 2018</last_update_submitted>
  <last_update_submitted_qc>May 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Seham Mohamed Moeen Ibrahim</investigator_full_name>
    <investigator_title>lecturer</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

